Sensei Biotherapeutics, Inc. (SNSE)

Market Cap	23.87M +141.6%
Revenue (ttm)	n/a
Net Income	-184.46M
EPS	-145.28
Shares Out	1.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,119
Open	18.47
Previous Close	17.79
Day's Range	17.29 - 19.16
52-Week Range	5.25 - 36.76
Beta	-0.18
Analysts	Strong Buy
Price Target	50.00 (+181.06%)
Earnings Date	May 15, 2026

About SNSE

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company’s pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in ea...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2021
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: SNSE
• Website: https://www.senseibio.com

Analyst Summary

According to one analyst, the rating for SNSE stock is "Strong Buy" and the 12-month stock price target is $50.0.

Price Target

$50.0

(181.06% upside)

Analyst Consensus: Strong Buy